Cargando…

LDL lowering effect of PCSK9 inhibition is reduced in women

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma low-density lipoprotein cholesterol (LDL-C) concentration, and its inhibition reduces the risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the sex-differential effect of either pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myasoedova, Veronika A, Rimbert, Antoine, Camera, Marina, Le May, Cedric, Capoulade, Romain, Cariou, Bertrand, Poggio, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236513/ https://www.ncbi.nlm.nih.gov/pubmed/36722156 http://dx.doi.org/10.1093/ehjcvp/pvad009

Ejemplares similares

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs
por: Roudaut, Meryl, et al.
Publicado: (2021)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
por: Perrot, Nicolas, et al.
Publicado: (2020)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
por: Deshycka, Rhogerry, et al.
Publicado: (2021)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia
por: Si-Tayeb, Karim, et al.
Publicado: (2016)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
por: Gadkar, K, et al.
Publicado: (2014)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE(−/−) Mice
por: Gu, Lili, et al.
Publicado: (2019)

A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates
por: Fowler, Alexandra, et al.
Publicado: (2023)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
por: Cariou, Bertrand, et al.
Publicado: (2013)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
por: Zhang, Liwen, et al.
Publicado: (2012)

Sex-Specific Cell Types and Molecular Pathways Indicate Fibro-Calcific Aortic Valve Stenosis
por: Myasoedova, Veronika A., et al.
Publicado: (2022)

The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats
por: Li, Xinyang, et al.
Publicado: (2020)

A Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies
por: Cui, Yimin, et al.
Publicado: (2021)

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
por: Katsuki, Shunsuke, et al.
Publicado: (2022)

Alpha-Lipoic Acid Reduces LDL-Particle Number and PCSK9 Concentrations in High-Fat Fed Obese Zucker Rats
por: Carrier, Bradley, et al.
Publicado: (2014)

In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor
por: Min, Dong-Kook, et al.
Publicado: (2015)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

FACS-assisted CRISPR-Cas9 genome editing of human induced pluripotent stem cells
por: Caillaud, Amandine, et al.
Publicado: (2022)

Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels
por: Jiang, Chuantao, et al.
Publicado: (2018)

PCSK9 induces a pro-inflammatory response in macrophages
por: Ricci, Chiara, et al.
Publicado: (2018)

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
por: Seidah, Nabil G., et al.
Publicado: (2012)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding
por: Deng, Shi-jun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5i4ifu6ckme0f9911q0pau0fpm